TY  - JOUR
AU  - Cortés, Alicia Arenas
AU  - Diaz, Rosa Ayala
AU  - Hernández-Campo, Pilar
AU  - Gorrochategui, Julián
AU  - Primo, Daniel
AU  - Robles, Alicia
AU  - Morales, María Luz
AU  - Ballesteros, Joan
AU  - Rapado, Inmaculada
AU  - Gallardo, Miguel
AU  - Linares, María
AU  - Martinez-Lopez, Joaquin
PY  - 2019
DO  - 10.3324/haematol.2018.201038
SN  - 0390-6078
UR  - http://hdl.handle.net/20.500.12105/9333
AB  - Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the...
LA  - eng
PB  - Fondazione Ferrata Storti
TI  - Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
TY  - journal article
ER  -